Century Therapeutics, Inc. (IPSC)
IPSC moved a median of -0.16% 30 minutes after news, and -0.87% by the close. How IPSC actually reacts to news — the realized, point-in-time move the market made, measured across 324 labeled events over the last three years with zero look-ahead.
IPSC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 321 |
| 30-min | -0.16% | 44% | 322 |
| 60-min | -0.22% | 48% | 323 |
| to close | -0.87% | 41% | 318 |
| Middle 50% of IPSC reactions | -1.43% to +1.35% |
|---|---|
| Median reaction (30-min) | -0.16% |
| Measured reactions | 324 |
Half of all Century Therapeutics, Inc. news events land between -1.43% and +1.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IPSC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | -0.43% | 40% | +2.28% |
| Rating reiterations | 32 | -0.71% | 25% | -0.64% |
| Price-target cuts | 10 | -1.85% | 20% | +1.14% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how IPSC ranks against every other measured name →
That’s how IPSC usually reacts — get an email when it moves on news →Email me when IPSC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IPSC's baseline. Nothing else.
Recent IPSC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London | Press release | GlobeNewswire | -2.94% | +1.47% | |
| Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 | Press release | GlobeNewswire | +0.61% | -6.71% | |
| Form 8-K Century Therapeutics, For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | -6.71% | |
| Century Therapeutics Appoints Joseph Truitt to Board of Directors | Press release | GlobeNewswire | -3.45% | -4.43% | |
| Form 8-K Century Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -3.45% | -4.43% | |
| Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | -0.72% | -5.77% | |
| Form 10-Q Century Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.72% | -5.77% | |
| Form 8-K Century Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | -5.77% | |
| Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 | Press release | GlobeNewswire | -1.65% | -4.94% | |
| Form 8-K Century Therapeutics, For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | +1.81% | |
| Form 8-K Century Therapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -1.29% | |
| Form 8-K Century Therapeutics, For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +1.89% | +4.25% | |
| New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 | Press release | GlobeNewswire | +1.89% | +4.25% | |
| Century Therapeutics Reports First Quarter Financial Results and Business Updates | Press release | GlobeNewswire | -0.87% | -0.87% | |
| Form 10-Q Century Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.87% | -0.87% | |
| Form 8-K Century Therapeutics, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.87% | -0.87% | |
| Century Therapeutics Selected for Oral Presentation of CNTY-813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions | Press release | GlobeNewswire | +0.36% | +0.43% | |
| Form DEF 14A Century Therapeutics, For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +0.45% | -1.34% | |
| Form DEFA14A Century Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.45% | -1.34% | |
| Form ARS Century Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +4.84% | |
| Form PRE 14A Century Therapeutics, For: Jun 11 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +4.84% | |
| Form 8-K Century Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | +0.00% | |
| Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates | Press release | GlobeNewswire | -1.72% | -13.79% | |
| Form 10-K Century Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.72% | -13.79% | |
| Form 8-K Century Therapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -1.72% | -13.79% | |
| Form S-8 Century Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -1.72% | -13.79% | |
| Century Therapeutics to Participate in Upcoming Investor Conferences in March | Press release | GlobeNewswire | +5.99% | +0.46% | |
| Form EFFECT Century Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +8.81% | |
| Form S-3 Century Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +3.29% | +1.80% | |
| Form 8-K Century Therapeutics, For: Jan 22 | SEC filing · Form 8-K | SEC EDGAR | -4.08% | +5.31% | |
| Form 8-K Century Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -4.38% | +5.16% | |
| Form EFFECT Century Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.27% | +11.17% | |
| Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes | Press release | GlobeNewswire | +5.82% | +12.03% | |
| Form 8-K Century Therapeutics, For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +5.82% | +12.03% | |
| Form S-3/A Century Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.50% | -8.15% | |
| Form 8-K Century Therapeutics, For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -1.47% | -2.06% | |
| Form 8-K Century Therapeutics, For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | +2.55% | |
| Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors | Press release | GlobeNewswire | +0.74% | +7.58% | |
| Form 8-K Century Therapeutics, For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | +7.58% | |
| Form DEF 14A Century Therapeutics, For: Jan 22 | SEC filing · Form DEF | SEC EDGAR | -1.23% | -4.57% | |
| Form DEFA14A Century Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.23% | -4.57% | |
| Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +0.84% | +1.89% | |
| Form PRE 14A Century Therapeutics, For: Jan 22 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +4.00% | |
| Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes | Press release | GlobeNewswire | -0.09% | — | |
| Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.09% | — | |
| Form 10-Q Century Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.09% | — | |
| Form 8-K Century Therapeutics, For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | — | |
| Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference | Press release | GlobeNewswire | +0.98% | +1.71% | |
| Form 8-K Century Therapeutics, For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | -2.26% | |
| Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | +0.04% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IPSC section they belong to.
Where else IPSC is measured.
IPSC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Century Therapeutics, Inc.'s median reaction calculated?
Every labeled IPSC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 324 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of IPSC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IPSC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.